Table 1.

Baseline characteristics of the study sample

CharacteristicsN (%) or mean (SD)BPH (%)No BPH (%)p
Total23,6222292 (9.7)21,330 (90.3)
Transplant recipient
    recipient age (years)48.24 (15.23)60.48 (10.04)46.92 (15.10)<0.001
    black race6653 (28.2)555 (24.2)6098 (28.6)<0.001
    years on dialysis prior to transplant3.31 (2.74)3.34 (2.62)3.31 (2.75)0.575
    Peak PRA >20%1798 (7.6)166 (7.2)1632 (7.7)0.072
    Comorbid conditions
        obstructive cause of ESRDa576 (2.4)48 (2.1)528 (2.5)0.286
        diabetes mellitus6066 (25.7)709 (30.9)5357 (25.1)<0.001
        congestive heart failure2421 (10.2)322 (14.0)2099 (9.8)<0.001
        ischemic heart disease2193 (9.3)350 (15.3)1843 (8.6)<0.001
        peripheral vascular disease1548 (6.6)206 (9.0)1342 (6.3)<0.001
        hypertension16,545 (70.0)1691 (73.8)14,854 (69.6)<0.001
        tobacco use1081 (4.6)80 (3.5)1001 (4.7)0.010
Transplant donor
    age >50 yr5186 (22.0)703 (30.7)4483 (21.0)<0.001
    black race3113 (13.2)258 (11.3)2855 (13.4)0.004
    deceased16,831 (71.3)1728 (75.4)15,103 (70.8)<0.001
    cold ischemic time >24 h3625 (15.3)432 (18.8)3193 (15.0)<0.001
    donation after cardiac death688 (2.9)65 (2.8)623 (2.9)0.890
    expanded criteria donorb2423 (10.3)391 (17.1)2032 (9.5)<0.001
    delayed graft functionc4853 (20.5)504 (22.0)4349 (20.4)0.072
Year of transplant<0.001
    2000 to 20018056 (34.1)701 (30.6)7355 (34.5)
    2002 to 20038610 (36.4)1001 (43.7)7609 (35.7)
    2004 to 20056,956 (29.4)590 (25.7)6366 (29.8)
Induction immunosuppression19,409 (82.2)1903 (83.0)17,506 (82.1)0.263
Discharge Immunosuppression
    Tacrolimus14,165 (60.0)1302 (56.8)12,863 (60.3)0.001
    Cyclosporine (Neoral®)5892 (24.9)609 (26.6)5283 (24.8)0.060
    Mycophenolate18,534 (78.5)1826 (79.7)16,708 (78.3)0.142
    Azathioprine560 (2.4)48 (2.1)512 (2.4)0.385
    Sirolimus3395 (14.4)304 (13.3)3091 (14.5)0.118
Number of HLA mismatches0.180
    0 to 25308 (22.8)514 (22.7)4794 (22.8)
    3 to 49592 (41.3)899 (39.7)8693 (41.4)
    5 to 68350 (35.9)851 (37.6)7499 (35.7)
  • Data given as the number (% of total) or mean ± one standard deviation (SD). BPH, benign prostatic hyperplasia; PRA, panel reactive antibody; ESRD, end stage renal disease; HLA, human leukocyte antigen.

  • a Obstructive cause of ESRD: USRDS diagnosis at listing (DGNL) codes for either chronic pyelonephritis (3007), acquired obstructive uropathy (3030), or chronic obstructive uropathy (3052)

  • b Expanded criteria donor: donor age >50 yr with history of two of the following (stroke, hypertension, creatinine >1.5 mg/dl) or donor age >60 yr

  • c Delayed graft function: need for dialysis within the 1st wk after transplant